BIIB:NGS-Biogen Inc. (USD)

EQUITY | Drug Manufacturers - General | Nasdaq Global Select

Last Closing

USD 208.9

Change

0.00 (0.00)%

Market Cap

USD 69.21B

Volume

1.88M

Analyst Target

USD 305.39
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-2.39 (-3.18%)

USD 233.63B
AMGN Amgen Inc

-0.46 (-0.15%)

USD 169.66B
SNY Sanofi ADR

-0.38 (-0.71%)

USD 136.24B
GILD Gilead Sciences Inc

+0.21 (+0.24%)

USD 108.60B
GRFS Grifols SA ADR

+0.57 (+6.95%)

USD 7.00B
AMRN Amarin Corporation PLC

-0.01 (-1.62%)

USD 0.26B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.47 (+27.17%)

USD 0.03B
SCLX Scilex Holding Company

-0.05 (-5.35%)

N/A
SCLXW Scilex Holding Company

+0.01 (+4.96%)

N/A

ETFs Containing BIIB

UBIO 6.30 % 0.95 %

N/A

N/A
BIS ProShares UltraShort Nasd.. 6.12 % 0.95 %

+0.17 (+0.17%)

USD 3.26M
XY7D:XETRA Global X S&P 500® Covere.. 5.61 % 0.00 %

-0.06 (0.17%)

N/A
XYLU:LSE Global X S&P 500® Covere.. 4.50 % 0.00 %

+0.02 (+0.17%)

USD 0.03B
BBH VanEck Biotech ETF 4.15 % 0.35 %

-0.05 (0.17%)

USD 0.45B
BTEC:SW iShares Nasdaq US Biotech.. 3.51 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 2.70 % 0.00 %

-0.02 (0.17%)

USD 0.52B
2B70:F iShares NASDAQ US Biotech.. 2.69 % 0.00 %

N/A

USD 0.52B
IBBQ Invesco Nasdaq Biotechnol.. 2.68 % 0.00 %

-0.11 (0.17%)

USD 0.04B
USMV:LSE Ossiam US Minimum Varianc.. 2.67 % 0.00 %

-0.53 (0.17%)

USD 0.01B
MVUS:PA 2.67 % 0.00 %

N/A

N/A
SPMV:PA 2.67 % 0.00 %

N/A

N/A
OSX2:XETRA Ossiam US Minimum Varianc.. 2.67 % 0.00 %

-2.25 (0.17%)

USD 0.12B
IBB iShares Biotechnology ETF 2.64 % 0.47 %

-0.01 (0.17%)

USD 7.39B
CURE:AU ETFS S&P Biotech ETF 2.52 % 0.00 %

+0.15 (+0.17%)

USD 0.04B
MRND 2.44 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 1.87 % 0.95 %

-0.61 (0.17%)

USD 0.09B
SCHZ Schwab U.S. Aggregate Bon.. 0.01 % 0.04 %

-0.03 (0.17%)

USD 8.38B
FLAG 0.00 % 1.52 %

N/A

N/A
MXDU 0.00 % 0.34 %

N/A

N/A
DQML 0.00 % 0.00 %

N/A

N/A
JAGG 0.00 % 0.07 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.17%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.17%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.13 (0.17%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.17%)

N/A
VCSH Vanguard Short-Term Corpo.. 0.00 % 0.07 %

-0.12 (0.17%)

USD 35.75B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.14 (0.17%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

+0.41 (+0.17%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.08 (+0.17%)

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-50.00 (0.17%)

N/A
XMWD:LSE Xtrackers MSCI World Swap.. 0.00 % 0.00 %

+0.04 (+0.17%)

N/A
CEM2:F 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

-3.00 (0.17%)

N/A
CEM2:XETRA 0.00 % 0.00 %

N/A

N/A
BIOT 0.00 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 0.00 % 0.00 %

+0.01 (+0.17%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.27% 40% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.27% 40% F 26% F
Trailing 12 Months  
Capital Gain -31.33% 44% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.33% 44% F 27% F
Trailing 5 Years  
Capital Gain -8.87% 43% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.87% 43% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 2.01% 56% F 52% F
Dividend Return 2.01% 56% F 48% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.98% 44% F 69% C-
Risk Adjusted Return 8.06% 56% F 48% F
Market Capitalization 69.21B 56% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.00 57% 35%
Price/Book Ratio 1.95 56% 48%
Price / Cash Flow Ratio 19.66 44% 14%
Price/Free Cash Flow Ratio 17.22 22% 15%
Management Effectiveness  
Return on Equity 8.05% 71% 72%
Return on Invested Capital 5.61% 40% 70%
Return on Assets 4.86% 67% 85%
Debt to Equity Ratio 45.87% 63% 44%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector